Not all "quality-adjusted life years" are equal.
暂无分享,去创建一个
S A Marion | F. Wolfe | J. Esdaile | A. Anis | C. Marra | D. Guh | S. Marion | M. Gignac | A. Clarke | M. Najafzadeh | J M Esdaile | C A Marra | F Wolfe | A E Clarke | A H Anis | D P Guh | M Najafzadeh | M A Gignac | J. Esdaile | Ann E. Clarke | Carlo A. Marra | Monique A. Gignac | Mehdi Najafzadeh
[1] Jacek A Kopec,et al. A comparative review of four preference-weighted measures of health-related quality of life. , 2003, Journal of clinical epidemiology.
[2] J. Wong,et al. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. , 2002, The American journal of medicine.
[3] J. Thumboo,et al. A comparison of the EuroQol-5D and the Health Utilities Index mark 3 in patients with rheumatic disease. , 2003, The Journal of rheumatology.
[4] Norman E. Breslow,et al. The design and analysis of cohort studies , 1987 .
[5] A. Anis,et al. The Indirect Costs of Arthritis Resulting From Unemployment, Reduced Performance, and Occupational Changes While at Work , 2006, Medical care.
[6] Emilio Vargas,et al. Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study. , 2003, Arthritis and rheumatism.
[7] Andrew H Briggs,et al. Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. , 2002, Annual review of public health.
[8] D. Lubeck,et al. Direct and indirect medical costs incurred by Canadian patients with rheumatoid arthritis: a 12 year study. , 1997, The Journal of rheumatology.
[9] J. Reginster,et al. The effect of health related quality of life on reported use of health care resources in patients with osteoarthritis and rheumatoid arthritis: a longitudinal analysis. , 2002, The Journal of rheumatology.
[10] N. E. Breslow. Statistical Methods in Cancer Research , 1986 .
[11] A. Brennan,et al. Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. , 2004, Rheumatology.
[12] A. Brennan,et al. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden , 2004, Annals of the rheumatic diseases.
[13] N. Breslow,et al. Statistical methods in cancer research. Volume II--The design and analysis of cohort studies. , 1987, IARC scientific publications.
[14] J. Kopec,et al. A Comparison of Four Indirect Methods of Assessing Utility Values in Rheumatoid Arthritis , 2004, Medical care.
[15] M. Weinstein,et al. A Comparison of HU12 and HU13 Utility Scores in Alzheimer's Disease , 2000, Medical decision making : an international journal of the Society for Medical Decision Making.
[16] M. Drummond,et al. OMERACT 6 Economics Working Group report: a proposal for a reference case for economic evaluation in rheumatoid arthritis. , 2003, The Journal of rheumatology.
[17] Jacek A Kopec,et al. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. , 2005, Social science & medicine.
[18] F. Wolfe. The psychometrics of functional status questionnaires: room for improvement. , 2002, The Journal of rheumatology.
[19] Andrew Briggs,et al. Cost-effectiveness and cost-utility of long-term management strategies for heartburn. , 2002, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[20] T. Pincus,et al. Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis. , 2003, Arthritis and rheumatism.
[21] L. Jönsson,et al. The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. , 2003, Rheumatology.
[22] Hyon K. Choi,et al. Predicting mortality in patients with rheumatoid arthritis. , 2003, Arthritis and rheumatism.
[23] J F Fries,et al. The clinical value of the Stanford Health Assessment Questionnaire Functional Disability Index in patients with rheumatoid arthritis. , 1988, The Journal of rheumatology.
[24] M. Brown,et al. GAIN OF FUNCTION ANKH VARIANTS CAUSE BOTH FAMILIAL AND SPORADIC CALCIUM PYROPHOSPHATE DIHYDRATE CHONDROCALCINOSIS , 2004 .
[25] P. Lipsky,et al. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial , 1999, The Lancet.
[26] M. Suarez‐Almazor,et al. Variation in the Estimation of Quality‐adjusted Life‐years by Different Preference‐based Instruments , 2003, Medical care.
[27] M. Drummond,et al. Health Care Technology: Effectiveness, Efficiency and Public Policy@@@Methods for the Economic Evaluation of Health Care Programmes , 1988 .
[28] S. Marion,et al. Estimating mortality rates: the role of proportional life expectancy. , 2005, Journal of insurance medicine.